Two companion posts on treating each N-of-1 as a prototype — and scaling it to every subsequent patient carrying the same variant.
Cure Odysseys is the Substack where Ethan Perlstein writes the inside view of each Perlara program: the family, the yeast model, the hit list, the N-of-1 protocol, and what fails. It doubles as our real-time lab notebook — not just a marketing channel.
The flagship Perlara program. 40-patient Phase III at Mayo Clinic Minnesota; an aldose-reductase inhibitor approved in Japan, repurposed.
Recurring deep-dives on humanized yeast strains for specific variants: FOXG1, SURF1, ECHS1, DHDDS, NARS1, PIGW, PIGN, ADSL, ALG11, PMM2, GNAO1, PGAP3.
Posts on paradoxical repurposing — inhibiting the compensating enzyme (GMPPB in GMPPA-CDG), restoring aldose reductase balance (PMM2-CDG).
The running argument: big pharma systematically declines IMDs, and the systematic decline is itself the opportunity.
A curated index of foundational, recent, and high-signal posts.